FOLFOXIRI plus Bevacizumab for Metastatic Colorectal Cancer
Published: | Updated:
Chiara Cremolini, MD, discusses the phase III TRIBE trial, which compared FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as for patients with metastatic colorectal cancer.
